Clinical Trial Update: A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Pertuzumab added to chemotherapy and Trastuzumab as adjuvant therapy for HER2-positive primary breast cancer; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• Perjeta (pertuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2018-01-05